Notably, tumor-intrinsic YTHDF1 depletion can elevate PD-L1 levels in vivo yet still sensitize tumors to immune attack—an apparent inconsistency that likely reflects dominant effects on the antigen-presentation axis and T-cell priming that outweigh PD-L1 upregulation per se (87, 88). Here, YTHDF1 is linked to neoplasm.